To evaluate the effect of select baseline characteristics on geographic atrophy (GA) progression in eyes receiving intravitreal pegcetacoplan or sham.

Phase 2 multicenter, randomized, single-masked, sham-controlled trial.

Patients with GA received 15 mg pegcetacoplan monthly or every other month (EOM), or sham injection monthly or…[Read more]